| 29.2 1.49 (5.38%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.18 | 1-year : | 41.09 |
| Resists | First : | 30.12 | Second : | 35.18 |
| Pivot price | 27.29  |
|||
| Supports | First : | 26.52 | Second : | 24.3 |
| MAs | MA(5) : | 27.61 |
MA(20) : | 27.39 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 67.3 |
D(3) : | 56.1 |
| RSI | RSI(14): 57.6 |
|||
| 52-week | High : | 32 | Low : | 24.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BRVE ] has closed below upper band by 6.0%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 29.54 - 29.65 | 29.65 - 29.76 |
| Low: | 27.18 - 27.31 | 27.31 - 27.44 |
| Close: | 28.98 - 29.19 | 29.19 - 29.4 |
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Thu, 17 Sep 2026
Short Interest in Braveheart Bio, Inc. (NASDAQ:BRVE) Rises By 64.8% - MarketBeat
Wed, 16 Sep 2026
Braveheart Bio to Participate in Stifel Cardiometabolic Forum - The Manila Times
Wed, 16 Sep 2026
Braveheart Bio (NASDAQ:BRVE) Trading 5.9% Higher - Here's Why - MarketBeat
Mon, 14 Sep 2026
BRVE Price History for Braveheart Bio Stock - Barchart.com
Thu, 10 Sep 2026
OrbiMed's stake in Braveheart Bio (BRVE) falls without selling shares - Stock Titan
Wed, 09 Sep 2026
BRVE: Braveheart Bio, Inc. - Balance Sheet - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 68.5 (%) |
| Held by Institutions | 22.4 (%) |
| Shares Short | 848 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -15.62 |
| PEG Ratio | 0 |
| Price to Book value | -11.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -286.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|